The Major Advances of the Year in Breast Cancer: A Point of View After the ASCO 2025 Annual Meeting
{{output}}
At ASCO 2025, several practice-changing studies in breast cancer were presented. In HR+ early BC, the SOFT/TEXT 15-year update confirmed the benefit of ovarian suppression plus endocrine therapy, while OASIS-4 showed elinzanetant reduced endocrine-related vaso... ...
